Results 121 to 130 of about 16,733 (229)

Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates

Microbiology Spectrum
The combination of aztreonam with ceftazidime/avibactam is considered a potential therapeutic approach for the treatment of infections caused by metallo-β-lactamase (MBL)-producing isolates.
Peipei Song, Jian Xu, Lan Jiang, Qin Zhang, Chenggui Liu   +4 more
doaj   +1 more source

Drug Resistance and Epidemiological Analysis of Carbapenem‐Resistant Enterobacteriaceae in a Brain and Psychiatric Hospital of South China

Journal of Clinical Laboratory Analysis, Volume 39, Issue 15, August 2025.
Detection time and department distribution of each isolate of CRKP and its clustering distribution indicator, the number codes the strain, for example 01=K2021001. ABSTRACT Background Carbapenem‐resistant Enterobacteriaceae (CRE) has increasingly become a global health problem, and the drug resistance and epidemiology of its infection are important for
Lei Yue, Xiumei Zhu, Yuyan Kuang, Yulong Lin, Haiying Liu   +4 more
wiley   +1 more source

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control, 2018
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often accompanied by ...
Wenxia Zhang, Yan Guo, Jiayin Li, Yiyuan Zhang, Yang Yang, Dong Dong, Demei Zhu, Ping He, Fupin Hu   +8 more
doaj   +1 more source

Unveiling carbapenem resistance: mechanism and therapeutic strategies [PDF]

This review provides an overview of the carbapenem resistance, its underlying causing microbes, its mechanism of transmission, risk factors, and its treatment options and challenges. Carbapenem resistance in Gram-negative organisms such as E. coli and K.
A., Sanjana, H., Fiza S., R., Thanushree D., U., Mounashree   +3 more
core   +2 more sources

Prevalence of Antimicrobial Resistance in Klebsiella pneumoniae in the South African Populations: A Systematic Review and Meta‐Analysis of Surveillance Studies

MicrobiologyOpen, Volume 14, Issue 4, August 2025.
Klebsiella pneumoniae isolates in South Africa exhibit > 50% resistance to first‐line antibiotics, with rising carbapenem resistance. Urgent, targeted interventions and genomic surveillance are essential to curb the spread of multidrug‐resistant strains and preserve treatment efficacy.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Longitudinal Analysis of the In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected in the Middle East/Africa Region for the ATLAS Surveillance Program, 2018-2022

International Journal of Infectious Diseases
Introduction: Enterobacterales commonly produce β-lactamases that can render members of the β-lactam class of antibacterial agents ineffective. Avibactam is a β-lactamase inhibitor active against class A, class C, and certain class D serine β-lactamases ...
Dr Mark Wise, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source

Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients [PDF]

Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications.
, , Bos, Jeroen, de Haan, Angela, den Boer, Hans, Hendrickx, Antoni P.A., Langerak, Diana, Notermans, Daan W., van Westreenen, Mireille, Verkaik, Nelianne J., Vogel, Marius, Wielders, Cornelia C.H., Witteveen, Sandra   +12 more
core   +3 more sources

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Journal of Antimicrobial Chemotherapy, 2020
Abstract Background Aztreonam is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs) and avibactam is a non-β-lactam β-lactamase inhibitor that effectively inhibits serine carbapenemases (CPs). Aztreonam/avibactam is under clinical development for treatment of serious infections caused by
Helio S, Sader, Cecilia G, Carvalhaes, S J Ryan, Arends, Mariana, Castanheira, Rodrigo E, Mendes   +4 more
openaire   +2 more sources

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Infection and Drug Resistance, 2023
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J, Zhang Y, Lu B, Chen H, Zhang Y, Li H, Wang Y, Wang Q, Wang H, Wang X   +9 more
doaj  

J Antimicrob Chemother [PDF]

BackgroundAztreonam/avibactam is a combination agent that shows promise in treating infections caused by highly antibiotic-resistant MBL-producing Enterobacterales.

core